Kala Pharmaceuticals Stock Current Valuation
| KALA Stock | USD 6.92 0.12 1.76% |
Valuation analysis of Kala Pharmaceuticals helps investors to measure Kala Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Kala Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Kala Pharmaceuticals is based on 3 months time horizon. Increasing Kala Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kala Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kala Stock. However, Kala Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.92 | Real 9.15 | Hype 7.12 | Naive 7.61 |
The real value of Kala Stock, also known as its intrinsic value, is the underlying worth of Kala Pharmaceuticals Company, which is reflected in its stock price. It is based on Kala Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kala Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kala Pharmaceuticals helps investors to forecast how Kala stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kala Pharmaceuticals more accurately as focusing exclusively on Kala Pharmaceuticals' fundamentals will not take into account other important factors: Kala Pharmaceuticals Company Current Valuation Analysis
Kala Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Kala Pharmaceuticals Current Valuation | 29.26 M |
Most of Kala Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kala Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Kala Pharmaceuticals has a Current Valuation of 29.26 M. This is 99.8% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.82% higher than that of the company.
Kala Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kala Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kala Pharmaceuticals by comparing valuation metrics of similar companies.Kala Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Kala Fundamentals
| Return On Equity | -4.31 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 29.26 M | ||||
| Shares Outstanding | 6.09 M | ||||
| Shares Owned By Insiders | 4.12 % | ||||
| Shares Owned By Institutions | 58.58 % | ||||
| Number Of Shares Shorted | 300.69 K | ||||
| Price To Earning | (0.52) X | ||||
| Price To Book | 6.04 X | ||||
| Price To Sales | 1.16 X | ||||
| Gross Profit | 1.33 M | ||||
| EBITDA | (36.08 M) | ||||
| Net Income | (42.2 M) | ||||
| Cash And Equivalents | 44.57 M | ||||
| Cash Per Share | 30.44 X | ||||
| Total Debt | 36.32 M | ||||
| Debt To Equity | 4.77 % | ||||
| Current Ratio | 2.54 X | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | (27.93 M) | ||||
| Short Ratio | 3.10 X | ||||
| Earnings Per Share | (11.67) X | ||||
| Target Price | 15.0 | ||||
| Number Of Employees | 43 | ||||
| Beta | -2.2 | ||||
| Market Capitalization | 41.42 M | ||||
| Total Asset | 55.95 M | ||||
| Retained Earnings | (629.41 M) | ||||
| Working Capital | 44.52 M | ||||
| Current Asset | 84.65 M | ||||
| Current Liabilities | 10.53 M | ||||
| Net Asset | 55.95 M |
About Kala Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kala Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:Check out Kala Pharmaceuticals Piotroski F Score and Kala Pharmaceuticals Altman Z Score analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.